GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (OCSE:NSIS B) » Definitions » EV-to-EBITDA

Novonesis (Novozymes) B (OCSE:NSIS B) EV-to-EBITDA : 36.14 (As of Jul. 03, 2025)


View and export this data going back to 2000. Start your Free Trial

What is Novonesis (Novozymes) B EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Novonesis (Novozymes) B's enterprise value is kr221,165 Mil. Novonesis (Novozymes) B's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was kr6,119 Mil. Therefore, Novonesis (Novozymes) B's EV-to-EBITDA for today is 36.14.

The historical rank and industry rank for Novonesis (Novozymes) B's EV-to-EBITDA or its related term are showing as below:

OCSE:NSIS B' s EV-to-EBITDA Range Over the Past 10 Years
Min: 17.35   Med: 24.89   Max: 48.12
Current: 36.15

During the past 13 years, the highest EV-to-EBITDA of Novonesis (Novozymes) B was 48.12. The lowest was 17.35. And the median was 24.89.

OCSE:NSIS B's EV-to-EBITDA is ranked worse than
79.67% of 1279 companies
in the Chemicals industry
Industry Median: 14.14 vs OCSE:NSIS B: 36.15

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-07-03), Novonesis (Novozymes) B's stock price is kr451.90. Novonesis (Novozymes) B's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was kr7.384. Therefore, Novonesis (Novozymes) B's PE Ratio (TTM) for today is 61.20.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Novonesis (Novozymes) B EV-to-EBITDA Historical Data

The historical data trend for Novonesis (Novozymes) B's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B EV-to-EBITDA Chart

Novonesis (Novozymes) B Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.64 28.59 16.94 18.66 24.29

Novonesis (Novozymes) B Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.66 36.12 40.62 24.29 32.31

Competitive Comparison of Novonesis (Novozymes) B's EV-to-EBITDA

For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novonesis (Novozymes) B's EV-to-EBITDA Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Novonesis (Novozymes) B's EV-to-EBITDA falls into.


;
;

Novonesis (Novozymes) B EV-to-EBITDA Calculation

Novonesis (Novozymes) B's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=221165.266/6119.206
=36.14

Novonesis (Novozymes) B's current Enterprise Value is kr221,165 Mil.
Novonesis (Novozymes) B's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr6,119 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novonesis (Novozymes) B  (OCSE:NSIS B) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Novonesis (Novozymes) B's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=451.90/7.384
=61.20

Novonesis (Novozymes) B's share price for today is kr451.90.
Novonesis (Novozymes) B's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr7.384.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Novonesis (Novozymes) B EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Novonesis (Novozymes) B's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Novonesis (Novozymes) B Business Description

Address
Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.

Novonesis (Novozymes) B Headlines

No Headlines